Revenue

BsStrategy's latest platform update signals a major shift in AI finance, where robust infrastructure and risk control are eclipsing the hunt for magic algorithms.

PVP Labs' new drug offers potent pain relief without addiction risk. A landmark DEA ruling clears it as a non-controlled substance, set to reshape medicine.

The logistics firm's recognition as a climate leader highlights an industry race where sustainability is now a key competitive and strategic advantage.

With fresh capital, the Swedish biotech is scaling its revolutionary platform that decodes cellular communication, fueling a major US expansion.

A new partnership delivers a domestically-made BESS control system, tackling strict federal regulations and securing the US clean energy supply chain.

A $1M donation marks a quarter-century partnership between Kohl's and Children's Wisconsin, funding a crucial fight against the state's youth mental health crisis.

A strategic merger between Tenet’s AI platform and Crown’s air freight legacy aims to create a unified, end-to-end solution for North American carriers.

A Boston biotech is using AI and targeted mRNA to program cells inside the body, aiming to make complex CAR T treatments safer and universally accessible.

Fintech firm Wahed launches a first-of-its-kind, zero-debt real estate fund for all US investors, opening the single-family rental market for just $100.

A new study shows high success for VVT Med's ScleroSafe varicose vein treatment, but a closer look reveals the need for more long-term data.

A new survey reveals 70% of Americans feel unready for property emergencies, exposing a dangerous gap between rising climate anxiety and actual preparedness.

As life-saving gene therapies face billion-dollar payment hurdles, a key appointment signals a strategic shift from scientific breakthrough to market access.

A new partnership promises to slash security analyst workload by 75% using agentic AI, signaling a major shift in how cybersecurity is managed globally.

The bank reported $4.9M in net income, driven by a late-quarter surge in loans and low-cost deposits, signaling a strong start to 2026.

New pre-clinical data shows engineered immune cells (iMacrophages) can effectively target and destroy ovarian tumors, offering hope for a new treatment era.

As 1,000 private jets descend on Louisville, Sentient Jet marks a decade of redefining the Kentucky Derby experience with exclusive access and high-flying luxury.

A new IDEO report quantifies how specific workplace behaviors create a $10 billion profit gap, proving that how a company operates is its biggest asset.

Biotech firm Scribe Therapeutics, co-founded by a Nobel laureate, is pioneering a new gene therapy for high cholesterol that silences genes, not cuts them.

After a record 2025 but a mixed Q4, the aerospace supplier's upcoming earnings will reveal its resilience against renewed supply chain disruptions.

With over 80% of AI projects failing, a new diagnostic test from MobiDev aims to help executives understand why and how to salvage their investments.